Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an update.
Alligator Bioscience announced new data on its immuno-oncology drugs, mitazalimab and ATOR-4066, at the SITC 40th Anniversary Annual Meeting. The data on mitazalimab, from the OPTIMIZE-1 trial in metastatic pancreatic cancer, supports the selection of a 900 μg/kg dose for a planned Phase 3 study, showing improved survival outcomes and manageable safety. Preclinical findings on ATOR-4066 demonstrate its potential in immune activation and tumor microenvironment remodeling, highlighting its superior efficacy compared to CD40 monospecific antibodies.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company focused on developing clinical-stage tumor-directed antibody drugs, particularly in the field of immuno-oncology.
Average Trading Volume: 964,857
Technical Sentiment Signal: Sell
Current Market Cap: SEK85.33M
For detailed information about ATORX stock, go to TipRanks’ Stock Analysis page.